Co-transplantation of hiPSC-Derived Mesenchymal Stem Cells and Cardiomyocytes Enhances Cardiac Regeneration After Myocardial Infarction

• Published in: Physiology (Bethesda, Md.) Md.), 2024-05, Vol.39 (S1)
• Main Authors: Sridharan, Divya, Alvi, Syed Baseeruddin, Mergaye, Muhamad, Ahmed, Uzair, Forehand, Abbey, Nottke, Katie, Khan, Mahmood
• Format: Article
• Language: English
• ISSN: 1548-9213; 1548-9221
• DOI: 10.1152/physiol.2024.39.S1.485

Abstract only Nearly a billion cardiomyocytes (CMs) are lost during an acute myocardial infarction (AMI) which eventually leads to heart failure. While most conventional treatments for AMI are only palliative, transplantation of human induced pluripotent stem cell (hiPSC)-derived cardiomyocytes (hiPSC-CMs) has been shown to improve cardiac function. However, the use of hiPSC-CMs has been limited by their poor engraftment and survival in the ischemic microenvironment post-MI. Since hiPSC-derived mesenchymal stem cells (hiPSC-MSCs) have been shown to promote cardioprotection via paracrine mechanisms, we hypothesized that co-transplantation of hiPSC-CMs and hiPSC-MSCs in ischemic hearts may improve cardioprotection and engraftment of transplanted hiPSC-CMs. We co-cultured hiPSC-CMs and hiPSC-MSCs and assessed the changes in morphology (TEM, ICC), gene expression (qRT-PCR), and cardiac function (MEA, and calcium transients) under normoxia and hypoxia (1% O 2 ). We observed increased maturation (elevated β-MHC expression, higher amplitude of contraction, increased sarcomere alignment) in hiPSC-CMs cultured in hiPSC-MSC derived conditioned medium. On the other hand, we observed enhanced survival (TUNEL assay) of hiPSC-CMs co-cultured with hiPSC-CMs following hypoxic insult. Additionally, following intramyocardial transplantation of (a) hiPSC-CMs, (b) hiPSC-MSCs or (c) hiPSC-CMs + hiPSC-MSCs (3:1) in a mouse MI model, we observed improved cardiac function, LVEF (p < 0.01) and FS (p